Literature DB >> 25921265

Novel type of plasmin inhibitors: providing insight into P4 moiety and alternative scaffold to pyrrolopyrimidine.

Naoki Teno1, Keigo Gohda2, Keiko Wanaka3, Yuko Tsuda4, Maiko Akagawa5, Eriko Akiduki5, Mitsuhito Araki5, Arisa Masuda5, Tadamune Otsubo5, Yukiko Yamashita6.   

Abstract

Here we report a series of plasmin inhibitors which were originally derived from the parent structure of 1 and 2. Our efforts focused on the optimization of the P4 moiety of 2 and on the quest of alternative scaffold to pyrrolopyrimidine in the parent compounds. The results of the former gave us pivotal information on the further optimization of the P4 moiety in plasmin inhibitors and those of the latter revealed that appropriate moieties extending from the benzimidazole scaffold engaged with S4 pocket in the active site of plasmin.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Benzimidazole; P4 moiety; Plasmin inhibitors; Pyrrolopyrimidine; Scaffold; Structure–activity relationship

Mesh:

Substances:

Year:  2015        PMID: 25921265     DOI: 10.1016/j.bmc.2015.04.013

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  2 in total

1.  Potent, Selective, Allosteric Inhibition of Human Plasmin by Sulfated Non-Saccharide Glycosaminoglycan Mimetics.

Authors:  Daniel K Afosah; Rami A Al-Horani; Nehru Viji Sankaranarayanan; Umesh R Desai
Journal:  J Med Chem       Date:  2017-01-05       Impact factor: 7.446

2.  Discovery of Orally Active and Nonsteroidal Farnesoid X Receptor (FXR) Antagonist with Propensity for Accumulation and Responsiveness in Ileum.

Authors:  Naoki Teno; Yusuke Iguchi; Keisuke Oda; Yukiko Yamashita; Arisa Masuda; Ko Fujimori; Mizuho Une; Keigo Gohda
Journal:  ACS Med Chem Lett       Date:  2021-02-24       Impact factor: 4.345

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.